We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA to Balance Premarket, Postmarket Data Requests

FDA to Balance Premarket, Postmarket Data Requests

April 10, 2015

The U.S. FDA plans to apply its least burdensome principle in deciding when to insist on premarket data in a PMA and when to allow the sponsor to gather additional clinical data postmarket.

Federal law requires the agency to request just enough data to assure a device’s safety and effectiveness and no more, meaning postmarket information may be used to reduce the amount of premarket data. This includes quality systems compliance, MDR reporting and postapproval studies, according to final guidance released Thursday.

The key to deciding how much premarket versus postmarket data is okay is the product’s impact on public health, the FDA says. For example, the agency may agree to accept more postmarket data to hasten approval of devices that address unmet medical needs or if it pertains to uncommon or minor risks. The agency also needs less premarket information to approve devices using technology that’s already well understood, the guidance says.

The balance could also tip in favor of more postmarket data if the device addresses an urgent public health need, such as a diagnostic to detect a spreading epidemic, or when the data is intended to confirm mitigation of known risks, the FDA says. Another reason for collecting postmarket data would be to gather information about a patient population beyond that addressed in the premarket study, the agency adds.

The guidance, Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval, was issued alongside one explaining the FDA’s new Expedited Access Program for devices filling unmet needs. It is expected to help agency staff balance premarket and postmarket information requests for devices on the EAP pathway (see related story).

View the guidance document at www.fdanews.com/04-13-15-balancing.pdf. — Elizabeth Orr

Regulatory Affairs Submissions and Approvals
  • Related Events

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing